0000000000320561

AUTHOR

J Ellis

showing 3 related works from this author

Review of Particle Physics

2020

The Review summarizes much of particle physics and cosmology. Using data from previous editions, plus 2,143 new measurements from 709 papers, we list, evaluate, and average measured properties of gauge bosons and the recently discovered Higgs boson, leptons, quarks, mesons, and baryons. We summarize searches for hypothetical particles such as supersymmetric particles, heavy bosons, axions, dark photons, etc. Particle properties and search limits are listed in Summary Tables. We give numerous tables, figures, formulae, and reviews of topics such as Higgs Boson Physics, Supersymmetry, Grand Unified Theories, Neutrino Mixing, Dark Energy, Dark Matter, Cosmology, Particle Detectors, Colliders, …

high energyleptonmixing [neutrino]High Energy Physics::LatticeCosmic microwave backgrounddiffractionTechnicolorAstrophysicsOmega01 natural sciencesPhysics Particles & Fieldshiggs-boson productionBig Bang nucleosynthesiscosmological model: parameter spacetaudark energyMonte CarlofieldspentaquarkinstrumentationSettore FIS/01gauge bosonAnomalous magnetic dipole momentdeep-inelastic scatteringnew physicsPhysicsDOUBLE-BETA-DECAYElectroweak interactiondensity [dark matter]HEAVY FLAVOURQuarkoniumreview; particle; physicsSUPERSYMMETRIC STANDARD MODELsquare-root-sPhysics Nucleargrand unified theoryboson: heavystatisticsPhysical SciencesHiggs bosonaxion: massflavor: violationNeutrinoELECTROWEAK SYMMETRY-BREAKINGnumerical calculations: Monte Carlophysicson-lineS013EPHQuarkheavy [boson]particle[PHYS.NUCL]Physics [physics]/Nuclear Theory [nucl-th]Physics Multidisciplinaryanomalous magnetic-momentelectroweak radiative-correctionsdark matter: densityHiggs particlemesonneutrino masses neutrino mixing; neutrino oscillations114 Physical sciencesCHIRAL PERTURBATION-THEORYneutrino mixingStandard Modelquark0202 Atomic Molecular Nuclear Particle And Plasma PhysicsNucleosynthesisquantum chromodynamicsCP: violationDark matterddc:530particle physicsStrong Interactions010306 general physicssparticleS013DFgrand unified theoriesPRODUCTIONGauge bosonScience & Technologyneutrino oscillationsneutrino masses010308 nuclear & particles physicsC50 Other topics in experimental particle physicsParticle Data GroupAstronomy and AstrophysicsDeep inelastic scatteringto-leading-order* Automatic Keywords *heavy bosonaxiontables (particle physics)Tetraquarkproton-proton collisionsSupersymmetryhadronneutrino: mixing[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]cosmologyVolume (compression)HIGGS-BOSONUB-VERTICAL-BARcosmological modeldark energy densityexperimental methodsddc:539.72021Physics beyond the Standard Modelstandard modelgroup theoryGeneral Physics and Astronomytables particle physicshigh energy physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Quantum chromodynamicsPhysicsenergy: highE Rev 2016[PHYS.HTHE]Physics [physics]/High Energy Physics - Theory [hep-th]Settore FIS/01 - Fisica SperimentalephotonSupersymmetryNuclear & Particles Physicsparameter space [cosmological model]dark energy: densityhigh [energy]M013WXfermion-pair productionNuclear and High Energy PhysicsParticle physicsHiggs bosonreviewAstrophysics::Cosmology and Extragalactic AstrophysicsAstronomy & Astrophysics530dark matterstatistical analysisDouble beta decay0103 physical sciencesconservation lawcold dark-matterTAU LEPTONSAstrophysics::Galaxy AstrophysicstablesDEEP-INELASTIC-SCATTERINGelectroweak interactionHigh Energy Physics::Phenomenology750 GeV diphoton excessPRODUCTION CROSS-SECTIONbaryondensity [dark energy]Physics and AstronomygravitationCKM matrix[PHYS.HPHE]Physics [physics]/High Energy Physics - Phenomenology [hep-ph]High Energy Physics::ExperimentsupersymmetryMinimal Supersymmetric Standard Model
researchProduct

Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic

2021

Association of Surgeons in Training Surgical Summit, online, 17 Oct 2020 - 17 Oct 2020 2021 Virtual Annual Meeting / Surgical Research Society, online, 24 Mar 2021 - 25 Mar 2021, National Research Collaborative Meeting, online, 10 Dec 2020 - 10 Dec 2020, Royal Australasian College of Surgeons Annual Academic Surgery Conference, online, 5 Nov 2020 - 5 Nov 2020; The British journal of surgery : BJS 108(12), 1448-1464 (2021). doi:10.1093/bjs/znab336

MaleRespiration Artificial/statistics & numerical dataSettore MED/18 - CHIRURGIA GENERALEeducation-Sciences du Vivant [q-bio]/Médecine humaine et pathologieAbdominal NeoplasmPostoperative Complications/mortalityNOsurgeryCohort Studies03 medical and health sciencesCOVID-19; death; SARS-CoV-2; surgery0302 clinical medicinePostoperative ComplicationsdeathHumans030212 general & internal medicinePandemicsAbdominal Neoplasms/surgeryAgedLS7_4COVID-19/mortalityRespiratory Distress SyndromePandemicSARS-CoV-2Respirationsurgical procedures operativemortalitysurgery specialtypandemicspulmonary complicationssars-cov-2covid-19coronavirus pandemicCOVID-19Middle Aged3126 Surgery anesthesiology intensive care radiologyRespiration Artificialsurgical proceduresoperativemortalitysurgery specialtypandemicspulmonary complicationssars-cov-2covid-19coronavirus pandemicAbdominal Neoplasms; Aged; COVID-19; Cohort Studies; Female; Humans; Male; Middle Aged; Pandemics; Postoperative Complications; Respiration Artificial; Respiratory Distress Syndrome; Elective Surgical ProceduresElective Surgical Procedures030220 oncology & carcinogenesisAbdominal NeoplasmsArtificialFemalePostoperative ComplicationCohort Studie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyRespiratory Distress Syndrome/mortalityHuman
researchProduct

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in…

0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
researchProduct